The drug buying agency will also remove the renewal criteria for people with ADHD and narcolepsy.

Advocacy group Aroreretini Aotearoa, says the changes will improve productivity for the ADHD community, by almost 57-million-dollars. Chief medical officer David Hughes says it will streamline ...

From 1 December 2024, Pharmac is also removing the renewal criteria for methylphenidate, dexamfetamine and modafinil, medicines used to treat ADHD and narcolepsy. This means that once an initial ...

The medicine - branded Lenvima - stops cancer cells from multiplying, slowing the disease's progression.

Pharmac has announced it'll fund new stimulant medicine lisdexamfetamine from December. The medicine -- branded as Vyvanse -- is taken once a day. Chief medical officer, David Hughes, says it's a ...

By AUT Journalism Student Vivek Panchal The Government has announced it will increase funding for Pharmac, boosting ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...

Christopher Luxon announced details of the Government's $604 million boost to the budget of New Zealand’s drug-buying agency ...

A resident’s rights under the Code of Health and Disability Services Consumers’ Rights (the Code) have been breached by ...

She says having another option out there means we're not so dependent on patches anymore, which is good news for a lot of ...

An overhaul of the way Pharmac decides to fund drugs for people with chronic long term diseases is needed, say health economists, who are asking the agency to consider the wider societal burden of the ...

A range of approaches is needed to manage mental health presentations. In this article, specialist GP Sophie Jadwiga Ball ...